Study: Aprotinin May Increase Mortality Rates In-Hospital

A study was conducted in Nova Scotia to assess the risks associated with aprotinin, which the authors hypothesized is associated with higher risk of adverse outcomes than tranexamic acid, according to MDLinx.

Advertisement

The retrospective study looked at 3,340 patients with cardiac surgery and in-hospital outcomes of postoperative mortality, new acute renal failure and perioperative blood transfusion.

Patients who received aprotinin were more often elderly and female. In-hospital mortality was significantly higher in the aprotinin group compared to the TXA group, up 5 percent. The ICU stay was also significantly increased in the aprotinin group, up 8.3 percent.

More Articles on Anesthesia:
Study: Type of General Anesthesia May Not Affect Risk of Myocardial Infarction
Anesthesiologist Dr. Rebecca Patchin to Serve as Joint Commission Board Chair
Marine Corps Searches for Smaller, More Rugged Anesthesia Machines

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Patient Safety & Outcomes

Advertisement

Comments are closed.